SpyGlass Pharma, a privately-held ophthalmic therapeutics company, today announced it will be unveiling a breakthrough drug delivery platform to treat chronic eye conditions at the Eyecelerator innovation meeting, being held prior to the American Academy of Ophthalmology (AAO) 2022 conference, September 29, in Chicago.